These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 3440875

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
    Decker DA, Al Sarraf M, Kresge C, Austin D, Wilner HI.
    J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
    Eagan RT, Dinapoli RP, Hermann RC, Groover RV, Layton DD.
    Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
    [Abstract] [Full Text] [Related]

  • 5. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
    Chamberlain MC, Prados MD, Silver P, Levin VA.
    J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
    [Abstract] [Full Text] [Related]

  • 6. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
    Tapazoglou E, Kish J, Ensley J, Al-Sarraf M.
    Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG, Yung WK, Leavens ME, Burgess MA, Obbens EA, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS.
    J Neurooncol; 1984 Aug; 2(1):13-7. PubMed ID: 6088722
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
    Sigman LM, Van Echo DA, Whitacre MY, Aisner J, Budman DA, Shulman P.
    Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
    Creagan ET, Schutt AJ, Ahmann DL, Green SJ.
    Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.
    Rubin J, van Hazel GA, Schutt AJ, Moertel CG, O'Connell MJ.
    Am J Clin Oncol; 1982 Oct; 5(5):539-40. PubMed ID: 7180832
    [Abstract] [Full Text] [Related]

  • 17. Treatment of patients with recurrent primary brain tumors with AZQ.
    Schold SC, Friedman HS, Bjornsson TD, Falletta JM.
    Neurology; 1984 May; 34(5):615-9. PubMed ID: 6538653
    [Abstract] [Full Text] [Related]

  • 18. Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma.
    Maral J, Poisson M, Pertuiset BF, Mashaly P, Weil M, Jacquillat C, Grillo-Lopez AJ.
    J Neurooncol; 1985 May; 3(3):245-9. PubMed ID: 4056853
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.
    Forastiere AA, Crain SM, Callahan K, Van Echo D, Mattox D, Thant M, Von Hoff DD, Wiernik PH.
    Cancer Treat Rep; 1982 Dec; 66(12):2097-8. PubMed ID: 6892491
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.